Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study To Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI (Regulate)

This study has been terminated.
(Clinical Hold)
Sponsor:
Collaborators:
The Cleveland Clinic
Duke Clinical Research Institute
Canadian VIGOUR Centre
Mount Sinai School of Medicine
Parexel
Information provided by (Responsible Party):
Regado Biosciences, Inc.
ClinicalTrials.gov Identifier:
NCT01848106
First received: May 2, 2013
Last updated: October 22, 2014
Last verified: October 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: August 2014
  Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)